Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
Age
5–11
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Child (male or female) aged 5 to 11 years inclusive
Provision of Subject Informed Consent Form for anonymous data collection and their subsequent use (must be signed by any of the parents)
The child must be included in an out-patient observation program at a medical institution for established bronchial asthma diagnosis for at least 1 year prior to enrolment and diagnosed with moderate to severe bronchial asthma at the time of enrolment
The child must have at least one documented bronchial asthma exacerbation in previous 1 year (including hospital admissions for bronchial asthma exacerbations, any cases of daytime hospital treatment without overnight stays and any cases of oral administration of glucocorticoids on an out-patient basis for \> 3 consecutive days)
Out-patient receiving step 3 controller treatments with fixed dose combinations of ICSs and LABA or treatment with separate administration of glucocorticoids and LABA in stable doses with adequate control of bronchial asthma symptoms
The patient administered with short-acting β2 agonists (inhalational) or rapidly released methylxanthines (oral) in the doses approved for the respective age as a rescue on-demand therapies during the preceding month
You may not be if
Cystic fibrosis, α1-antitrypsin deficiency or congenital abnormalities of lung development
Severe comorbidities affecting the patient's overall performance
In the physician's opinion, the patient is not able to comply with the protocol requirements
Expected specific hyposensibilization within next 6 months
Expected treatment at health resort facilities within next 6 months
Other reasons that in the physician's opinion will prevent reliable assessments of the study treatment efficacy
